Search results
Results from the WOW.Com Content Network
Controversies included data manipulation concerns and delayed reporting to regulatory agencies. Onasemnogene abeparvovec's price is high, earning it the title of the world's most expensive medication at the time of commercial approval. [10] This has later been exceeded by other gene therapies like Hemgenix. Japan negotiated a lower price for ...
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
In 2010, Alexion priced Soliris as the most expensive drug in the world, [27] at approximately US$409,500 a year in the United States (2010), [27] €430,000 per year for ongoing treatment in the UK, [28] [29] and $500,000 a year in Canada (2014). [30] In 2021, Soliris generated US$1.874 billion in sales. [31] [32]
Developed by Alexion Pharmaceuticals, Soliris is the most expensive drug in the world, at an average annual cost of $409,500. Soliris itself treats a rare blood disorder called paroxysmal ...
The most expensive drugs on the market are getting more expensive.
Drug price-comparison platform GoodRx recently released an expanded rundown of the 20 most costly drugs in the U.S., based on the list price set by manufacturers — which can be very different ...
Alipogene tiparvovec was expected to cost around US$1.6 million per treatment in 2012, [9] —revised to $1 million in 2015, [10] —making it the most expensive medicine in the world at the time. [11] However, replacement therapy, a similar treatment, can cost over $300,000 per year, for life. [4]
In December 2011, Alexion acquired Montreal-based Enobia Pharma, the developer of asfotase alfa, a drug used to treat the genetic disorder hypophosphatasia, for as much as $1.08 billion. [29] In June 2015, Alexion acquired Synageva, a maker of rare disease treatments, in an $8.4 billion stock-and-cash deal. [12] [30] [31] [13] [32] [33]